EMA Management Board: highlights of September 2026 meeting

Imported from official source

Announcement

Mid-year report 2026 from the Executive Director

EMA presented results and achievements of its operations for the first half of 2026 to the Management Board. Between January and June, applications for new human medicines (orphan and non-orphan) remained at the same high level as last year, with 29 applications received. For veterinary medicines, the Board noted that seven initial marketing authorisation applications had been received in the first half of 2026, compared with 12 in the same period in 2025. There has been a significant increase in requests for scientific advice for both human and veterinary medicines, indicating a sustained interest by developers to bring their innovative medicines to patients in the EU.

The Board welcomed EMA's progress in preparing for the implementation of the new pharmaceutical legislation and the Critical Medicines Act, including measures to strengthen the availability and supply of critical medicines across the EU. The Board also noted the Agency’s continued support for innovation through enhanced PRIME support, implementation of the Health Technology Assessment (HTA) Regulation, progress in advancing clinical trial initiatives under ACT EU and the expansion of DARWIN EU, to generate high-quality real-world evidence to complement regulatory decision-making. It also welcomed continued progress in the digital transformation of the European Medicines Regulatory Network, including advances in data and artificial intelligence initiatives. This work builds on the European Medicines Agencies Network Strategy to 2028 (EMANS 2028) and is guided by the Agency's vision of creating a fast path from innovation to safe and effective medicines.

The 2026 mid-year report will be published shortly.

Preparations for implementation of the new EU pharmaceutical legislation

This is an extract. The publication continues at the source.

Source: European Medicines Agency.

Read the original at the source: https://www.ema.europa.eu/en/news/ema-management-board-highlights-september-2026-meeting

Officially imported this from European Medicines Agency’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.

Provenance

Organization
European Medicines Agency — imported from official source
Official source
https://www.ema.europa.eu/en/news.xml RSS
Imported
October 03, 2026 20:30
Versions
1 recorded
Identity
https://www.ema.europa.eu/en/news/ema-management-board-highlights-september-2026-meeting

Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.